Tariffs’ Impact On Some Cannabis Businesses May Erase Any Benefits They See From 280E …
#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
“The real clinical problem we’re facing isn’t tariff policy or tax code—it’s that when small cannabis producers get squeezed by competing cost pressures, they cut corners on testing, quality control, and worker safety, and those shortcuts end up in my patients’ lungs and bloodstreams.”
The intersection of federal tax policy and cannabis business economics presents a nuanced challenge for clinicians advocating for patients in states where cannabis is legal. While the potential removal or modification of Internal Revenue Code Section 280E (which prohibits cannabis businesses from deducting ordinary business expenses) could theoretically improve product affordability and accessibility, concurrent tariff policies may offset these gains by increasing operational costs for cultivators and retailers. Healthcare providers should recognize that cannabis pricing and availability in their communities are shaped by complex fiscal policies beyond clinical considerations, and that patients’ out-of-pocket costs may remain elevated regardless of tax or tariff changes. When counseling patients about cannabis use for symptom management, clinicians should remain attuned to cost barriers that may influence adherence or drive patients toward unregulated products, while advocating for transparent information about how regulatory and fiscal environments affect the legal cannabis market they’re recommending.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
